201 related articles for article (PubMed ID: 19318491)
1. Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma.
Firoz EF; Warycha M; Zakrzewski J; Pollens D; Wang G; Shapiro R; Berman R; Pavlick A; Manga P; Ostrer H; Celebi JT; Kamino H; Darvishian F; Rolnitzky L; Goldberg JD; Osman I; Polsky D
Clin Cancer Res; 2009 Apr; 15(7):2573-80. PubMed ID: 19318491
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma.
Cotignola J; Chou JF; Roy P; Mitra N; Busam K; Halpern AC; Orlow I
J Invest Dermatol; 2012 May; 132(5):1471-8. PubMed ID: 22336942
[TBL] [Abstract][Full Text] [Related]
3. MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness.
Capasso M; Ayala F; Avvisati RA; Russo R; Gambale A; Mozzillo N; Ascierto PA; Iolascon A
J Hum Genet; 2010 Aug; 55(8):518-24. PubMed ID: 20535124
[TBL] [Abstract][Full Text] [Related]
4. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.
Sun YF; Leu JD; Chen SM; Lin IF; Lee YJ
BMC Cancer; 2009 Jan; 9():13. PubMed ID: 19144119
[TBL] [Abstract][Full Text] [Related]
5. MDM2 SNP309 promoter polymorphism confers risk for hereditary melanoma.
Thunell LK; Bivik C; Wäster P; Fredrikson M; Stjernström A; Synnerstad I; Rosdahl I; Enerbäck C
Melanoma Res; 2014 Jun; 24(3):190-7. PubMed ID: 24625390
[TBL] [Abstract][Full Text] [Related]
6. Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.
Leu JD; Wang CY; Tsai HY; Lin IF; Chen RC; Lee YJ
Oncol Rep; 2011 Jun; 25(6):1755-63. PubMed ID: 21479369
[TBL] [Abstract][Full Text] [Related]
7. Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.
Yu H; Huang YJ; Liu Z; Wang LE; Li G; Sturgis EM; Johnson DG; Wei Q
Mol Carcinog; 2011 Sep; 50(9):697-706. PubMed ID: 21656578
[TBL] [Abstract][Full Text] [Related]
8. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
9. Association between genetic polymorphisms in apoptosis-related genes and risk of cutaneous melanoma in women and men.
Oliveira C; Lourenço GJ; Rinck-Junior JA; Cintra ML; Moraes AM; Lima CS
J Dermatol Sci; 2014 May; 74(2):135-41. PubMed ID: 24461648
[TBL] [Abstract][Full Text] [Related]
10. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
11. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
Han JY; Lee GK; Jang DH; Lee SY; Lee JS
Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
[TBL] [Abstract][Full Text] [Related]
12. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N
Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782
[TBL] [Abstract][Full Text] [Related]
13. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
Wan Y; Wu W; Yin Z; Guan P; Zhou B
BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
[TBL] [Abstract][Full Text] [Related]
15. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
16. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
17. MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset.
Hamid S; Yang YH; Peng KN; Ismail SM; Zain RB; Lim KP; Wan Mustafa WM; Abraham MT; Teo SH; Cheong SC
Oral Oncol; 2009 Jun; 45(6):496-500. PubMed ID: 18804411
[TBL] [Abstract][Full Text] [Related]
18. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
[TBL] [Abstract][Full Text] [Related]
19. Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population.
Leu JD; Lin IF; Sun YF; Chen SM; Liu CC; Lee YJ
World J Gastroenterol; 2009 Nov; 15(44):5592-7. PubMed ID: 19938200
[TBL] [Abstract][Full Text] [Related]
20. Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer.
Hitzenbichler F; Stoehr CG; Rogenhofer M; Wieland WF; Ruemmele P; Hartmann A; Stoehr R
Pathobiology; 2014; 81(2):53-9. PubMed ID: 24217660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
